5AM Ventures appeared to be the VC, which was created in 2002. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Menlo Park.
The fund has no exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Audentes Therapeutics, Ikaria, Relypsa We can highlight the next thriving fund investment areas, such as Life Science, Therapeutics.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the 5AM Ventures, startups are often financed by Clarus Ventures, ARCH Venture Partners, Sprout Group. The meaningful sponsors for the fund in investment in the same round are Roche Venture Fund, Frazier Healthcare Partners, Clarus Ventures. In the next rounds fund is usually obtained by ARCH Venture Partners, Roche Venture Fund, Aravis Ventures.
The current fund was established by Andrew Schwab, John Diekman. Besides them, we counted 8 critical employees of this fund in our database.
The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 12 percentage points more often commits exit comparing to other companies. When the investment is from 5AM Ventures the average startup value is 10-50 millions dollars. Opposing the other organizations, this 5AM Ventures works on 8 percentage points less the average amount of lead investments. The top amount of exits for fund were in 2018. The fund is constantly included in 7-12 deals per year.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Latigo Biotherapeutics | $135M | 14 Feb 2024 | - | ||
GlycoEra | 05 Jan 2024 | Schlieren, Zurich, Switzerland | |||
Radionetics Oncology | $52M | 03 Jan 2024 | California City, California, United States | ||
Nouscom | $79M | 14 Nov 2023 | Basel, Basel-City, Switzerland | ||
MapLight Therapeutics | $225M | 30 Oct 2023 | Palo Alto, California, United States | ||
Precede Biosciences | $57M | 05 Oct 2023 | Boston, Massachusetts, United States | ||
Nvelop Therapeutics | $100M | 25 Sep 2023 | Cambridge, Massachusetts, United States | ||
Radionetics Oncology | $52M | 14 Aug 2023 | California City, California, United States | ||
Novome Biotechnologies | $43M | 13 Sep 2022 | South San Francisco, California, United States |
– Neurogastrx, a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced the successful completion of a $60m Series B crossover round led by Vivo Capital.
– Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors.
– Proceeds from the financing will be used to advance the company’s pipeline of GI therapies for serious conditions that impact millions of people yet are not effectively treated.
– TMRW Life Sciences, Inc., a NYC-based life sciences technology company providing an automated platform for tracking, monitoring, and storage of frozen eggs and embryos used in in vitro fertilization (IVF), completed a $105m Series C equity and debt financing.
– The equity round was led by Transformation Capital with participation from GV (formerly Google Ventures), Casdin Capital, Peter Thiel, Anne and Susan Wojcicki, and existing investors 5AM Ventures and Life Sciences Innovation Fund, among others.
– The company intends to use the funds to accelerate global expansion, advance product innovation, develop consumer awareness of the platform, and support future business development opportunities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Latigo Biotherapeutics | $135M | 14 Feb 2024 | - | ||
GlycoEra | 05 Jan 2024 | Schlieren, Zurich, Switzerland | |||
Radionetics Oncology | $52M | 03 Jan 2024 | California City, California, United States | ||
Nouscom | $79M | 14 Nov 2023 | Basel, Basel-City, Switzerland | ||
MapLight Therapeutics | $225M | 30 Oct 2023 | Palo Alto, California, United States | ||
Precede Biosciences | $57M | 05 Oct 2023 | Boston, Massachusetts, United States | ||
Nvelop Therapeutics | $100M | 25 Sep 2023 | Cambridge, Massachusetts, United States | ||
Radionetics Oncology | $52M | 14 Aug 2023 | California City, California, United States | ||
Novome Biotechnologies | $43M | 13 Sep 2022 | South San Francisco, California, United States |
